Cystic Fibrosis Canada has called on the federal government to halt implementation of regulatory changes to the Patented Medicines Price Review Board (PMPRB).
Changes to the comparator countries used by the PMPRB are deemed acceptable, but changes aimed at further reducing prices are creating an uncomfortable uncertainty and could make Canada an outlier amongst OECD countries, and a less desirable destination for drug manufacturers. They put access to game-changing medicines like Trikafta at risk and should be evaluated by an independent third party to avoid unintended negative consequences to patients.
Moreover, public consultations appear to have been largely symbolic, as little heed has been taken of the growing concerns of patients and patient groups. Going forward, the Government of Canada must ensure that the PMPRB and all related agencies immediately implement a formal mechanism for meaningful and continuous patient engagement on any matters that deal with access to medicines.
Back to Listing